The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review ...

The current FDA approval is limited to well-differentiated NET even though the phase 3 Cabinet trial enrolled a small number of patients with moderately-differentiated cancers.

The results showed that 24 of 32 patients with de-differentiated liposarcoma and MDM2 amplification had ... an MDM2-p53 antagonist. Additionally, all 15 patients with well-differentiated ...